X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Through the agreement, Pierre Fabre will access the development and global commercialization of Exarafenib, an investigational pan-RAF inhibitor, which is being evaluated in preclinical trial studies for the treatment of NRAS-mutated melanoma.
Lead Product(s): Exarafenib
Therapeutic Area: Oncology Product Name: Exarafenib
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pierre Fabre
Deal Size: $30.5 million Upfront Cash: Undisclosed
Deal Type: Agreement March 01, 2024
Details:
Through the acquisition, XOMA will get access to KIN-2787 (exarafenib), which is a potent and selective investigational small molecule pan-RAF inhibitor that is being evaluated for the BRAF/NRAS-mutated advanced or metastatic solid tumors.
Lead Product(s): Exarafenib,Binimetinib
Therapeutic Area: Oncology Product Name: KIN-2787
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: XOMA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 16, 2024
Details:
KIN-2787 (exarafenib) is an orally administered, potent and selective investigational small molecule pan-RAF inhibitor, designed to target BRAF Class II and Class III alterations, it is a potential treatment for NRAS mutation-positive melanoma.
Lead Product(s): Exarafenib,Binimetinib
Therapeutic Area: Oncology Product Name: KIN-2787
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Details:
KIN-2787, is an orally available small molecule pan-RAF inhibitor being developed for the treatment of patients with lung cancer, melanoma, and other solid tumors.
Lead Product(s): Exarafenib,Binimetinib
Therapeutic Area: Oncology Product Name: KIN-2787
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kinnate Biopharma
Deal Size: $24.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition February 21, 2023
Details:
KIN-2787 (exarafenib), is an orally available small molecule pan-RAF inhibitor being developed for the treatment of patients with lung cancer, melanoma, and other solid tumors.
Lead Product(s): Exarafenib,Binimetinib
Therapeutic Area: Oncology Product Name: KIN-2787
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
